Literature DB >> 15967095

Treatment of Medical Complications in Patients with Brain Tumors.

Amy A Pruitt1.   

Abstract

Patients with primary brain tumors and those with cerebral metastases are at risk throughout their illness for several major medical problems, including vasogenic edema, seizures, and symptomatic venous thrombosis. In turn, the corticosteroids, anti-epileptic drugs, and anticoagulants used to treat these problems may produce significant adverse effects and result in important drug-drug interactions that may complicate chemotherapy. Although few Class I studies address any of these issues, guidelines can be offered to maximize quality of life and minimize hospital readmissions. Optimal management of brain edema involves minimizing corticosteroid use and tapering the steroid dose slowly to avoid steroid withdrawal symptoms. Prophylaxis of Pneumocystis pneumonia is necessary for patients requiring corticosteroids for more than 1 month. Anti-epileptic drugs (AEDs) should be avoided unless patients experience seizures. If possible, non-CTY (P450) enzyme-inducing drugs should be chosen. AED levels should be obtained frequently during corticosteroid taper. Multimodality venous thrombosis prophylaxis should begin at the time of the original surgery with external leg compression and unfractionated subcutaneous heparin or a low molecular weight heparin (LMWH). Brain tumor patients with symptomatic venous thrombosis or pulmonary embolism can be anticoagulated safely with warfarin or with LMWH, and LMWHs are preferable from the standpoints of efficacy, safety, and convenience for long-term outpatient treatment of venous thrombosis. Clinicians should be aware of potential drug-drug interactions between prescribed AEDs and chemotherapy and possible interactions with complementary and alternative therapies chosen by their patients. They also should be aware of interventions to minimize late sequelae of brain tumors and their treatment, including cognitive decline, depression, and increased stroke risk.

Entities:  

Year:  2005        PMID: 15967095     DOI: 10.1007/s11940-005-0042-y

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.972


  53 in total

Review 1.  Corticosteroid supplementation for adrenal insufficiency.

Authors:  Douglas B Coursin; Kenneth E Wood
Journal:  JAMA       Date:  2002-01-09       Impact factor: 56.272

2.  Physicians should administer low-dose corticosteroids selectively to septic patients until an ongoing trial is completed.

Authors:  John M Luce
Journal:  Ann Intern Med       Date:  2004-07-06       Impact factor: 25.391

Review 3.  Cognitive, affective, and behavioral side events in adults secondary to antiepileptic drug use.

Authors:  Richard H Mattson
Journal:  Rev Neurol Dis       Date:  2004

4.  New insights into transmission, diagnosis, and drug treatment of Pneumocystis carinii pneumonia.

Authors:  J A Kovacs; V J Gill; S Meshnick; H Masur
Journal:  JAMA       Date:  2001-11-21       Impact factor: 56.272

5.  Phenytoin-induced severe cutaneous drug reactions: suspected interactions with corticosteroids and H2-blockers.

Authors:  A D Cohen; E Reichental; S Halevy
Journal:  Isr Med Assoc J       Date:  1999-10       Impact factor: 0.892

6.  Dose-effect relationship of dexamethasone on Karnofsky performance in metastatic brain tumors: a randomized study of doses of 4, 8, and 16 mg per day.

Authors:  C J Vecht; A Hovestadt; H B Verbiest; J J van Vliet; W L van Putten
Journal:  Neurology       Date:  1994-04       Impact factor: 9.910

7.  Venous thromboembolism occurs frequently in patients undergoing brain tumor surgery despite prophylaxis.

Authors:  A T Chan; A Atiemo; L K Diran; G P Licholai; P McLaren Black; M A Creager; S Z Goldhaber
Journal:  J Thromb Thrombolysis       Date:  1999-08       Impact factor: 2.300

Review 8.  Thromboembolism in brain tumors.

Authors:  D C Walsh; A K Kakkar
Journal:  Curr Opin Pulm Med       Date:  2001-09       Impact factor: 3.155

9.  Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial.

Authors:  Harry R Büller; Bruce L Davidson; Hervé Decousus; Alexander Gallus; Michael Gent; Franco Piovella; Martin H Prins; Gary Raskob; Annelise E M Segers; Roger Cariou; Oscar Leeuwenkamp; Anthonie W A Lensing
Journal:  Ann Intern Med       Date:  2004-06-01       Impact factor: 25.391

10.  Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions.

Authors:  K Hoang-Xuan; L Capelle; M Kujas; S Taillibert; H Duffau; J Lejeune; M Polivka; E Crinière; Y Marie; K Mokhtari; A F Carpentier; F Laigle; J M Simon; P Cornu; P Broët; M Sanson; J Y Delattre
Journal:  J Clin Oncol       Date:  2004-08-01       Impact factor: 44.544

View more
  4 in total

1.  End of life issues in brain tumor patients.

Authors:  Andrea Pace; Cherubino Di Lorenzo; Cherubino Di Lorenzo; Lara Guariglia; Bruno Jandolo; Carmine M Carapella; Alfredo Pompili
Journal:  J Neurooncol       Date:  2008-08-14       Impact factor: 4.130

2.  Ulceration of Striae distensae in high-grade glioma patients on concurrent systemic corticosteroid and bevacizumab therapy.

Authors:  Katherine B Peters; Thomas E Coyle; James J Vredenburgh; Annick Desjardins; Henry S Friedman; David A Reardon
Journal:  J Neurooncol       Date:  2010-06-04       Impact factor: 4.130

Review 3.  Medical management of patients with brain tumors.

Authors:  Patrick Y Wen; David Schiff; Santosh Kesari; Jan Drappatz; Debra C Gigas; Lisa Doherty
Journal:  J Neurooncol       Date:  2006-06-29       Impact factor: 4.130

4.  Cryptococcal meningitis in patients with glioma: a report of two cases.

Authors:  Jonathan D Choi; Ciaran J Powers; James J Vredenburgh; Allan H Friedman; John H Sampson
Journal:  J Neurooncol       Date:  2008-04-09       Impact factor: 4.130

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.